Qyuns Therapeutics (HKG:2509) has granted Caldera Therapeutics an exclusive right to develop and commercialize QX030N globally under an out-license agreement, a Thursday Hong Kong bourse filing said.
The biotechnology company will receive a one-time upfront payment of $10 million under the contract, as well as around 24.88% equity interest in Caldera Therapeutics.
The firm may also receive additional milestone payments of up to $545 million and tiered royalties.
QX030N is a long-acting bispecific antibody in the pre-clinical stage for the treatment of immunologic disorders.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。